Hypertension prevalence, awareness, treatment and control in the over 50s in Ireland: evidence from The Irish Longitudinal Study on Ageing by Murphy, Catriona et al.
Hypertension prevalence, awareness, treatment and control
in the over 50s in Ireland: evidence from The Irish Longitudinal
Study on Ageing
C.M. Murphy1, P.M. Kearney2, E.B. Shelley3, T. Fahey4, C. Dooley1, R.A. Kenny1
1The Irish Longitudinal Study on Ageing (TILDA), Department of Medical Gerontology, Trinity College, Lincoln Gate, Dublin 2, Ireland
2Department of Epidemiology and Public Health, University College Cork, Cork, Ireland
3Department of Public Health, Health Service Executive, Dublin, Ireland
4HRB Centre for Primary Care Research, Department of General Practice, Royal College of Surgeons Medical School, Dublin, Ireland
Address correspondence to Catriona M. Murphy, E-mail: catriona.murphy@tcd.ie
ABSTRACT
Background To assess the prevalence, awareness, treatment and control of hypertension among adults in Ireland and to describe the
determinants of awareness, treatment and control in order to inform public health policy.
Methods A cross-sectional study of a nationally representative sample of community living adults aged 50 years and older using data collected
from 2009 to 2011 for the first wave of the Irish Longitudinal Study on Ageing (TILDA) (n ¼ 5857). Hypertension was defined as systolic blood
pressure (BP) 140 mmHg or diastolic BP 90 mmHg and/or currently taking antihypertensive medications.
Results The prevalence of hypertension was 63.7% [95% confidence interval (CI) 62.3–65.1%]. Among those with hypertension, 54.5% (95%
CI 52.6–56.2%) were aware of their hypertensive status and 58.9% (95% CI 57.1–60.4%) were on antihypertensive medication. Among those
on treatment, 51.6% (95% CI 49.3–53.9%) had their BP controlled to below 140/90 mmHg. Respondents facing financial barriers to primary
care and medication were less likely to be on antihypertensive treatment compared with those without financial barriers.
Conclusions A high prevalence of hypertension was identified in this cohort, with low levels of awareness, treatment and control. Population
and primary care interventions are required to reduce prevalence and to improve awareness, detection and management of hypertension.
Keywords adult, aged, awareness, cross-sectional studies, epidemiology, hypertension, Ireland, prevalence
Introduction
Cardiovascular diseases (CVDs) account for one-third of
mortality globally1 and an almost identical proportion of
deaths in Ireland.2 Despite a dramatic drop in mortality rates
since 1998, CVD remains the leading cause of death in
Ireland.3 This decline in cardiovascular mortality is attributed
to a combination of improved treatment uptake (40%) and an
improvement in risk factors (48%).4 Hypertension is a leading
modiﬁable risk factor for CVD and estimated to be respon-
sible for at least 45% of ischaemic heart disease mortality and
51% of total stroke mortality globally.5
The burden of hypertension is increasing worldwide.6 It
was estimated that there were 972 million adults worldwide
with hypertension in 2000. In the context of an ageing
population, this is expected to increase by 60% to reach 1.5
billion by 2025.7 Ireland is a relatively young country with 1.2
million (28%) of the population aged 50 years and older in
2011.8 The number of people in this age group is expected to
increase to between 2.1 and 2.4 million by 2046.9 This abso-
lute increase in the number of older adults in the population
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will place a considerable burden on health services to prevent,
identify and manage hypertension in order to prevent the
more costly management of the complications of hyperten-
sion.10,11 Previous research on a subsample of adults aged
45 years and older taken from a nationally representative
sample of adults aged 18 years and older found a hyperten-
sion prevalence of 60% in 2007.12 Recent data on the preva-
lence, awareness, treatment and control of hypertension in the
Irish population are lacking. The aim of this study is to
provide an estimate of the prevalence of hypertension in older
adults in Ireland and to describe the determinants of aware-
ness, treatment and control of hypertension in order to
inform public health policy.
Methods
Study setting and participants
This study is cross-sectional in design using data from the ﬁrst
wave of the Irish Longitudinal Study on Ageing (TILDA).
TILDA is a population-based prospective cohort study, repre-
sentative of the community living older population in Ireland.
The sample was recruited based on a national directory of resi-
dential addresses using the RANSAM system.13 Each member
of the population in Ireland aged 50 years and older had an
equal probability of being invited to participate. Ethical approv-
al for the study was received from the Trinity College Research
Ethics Committee and all participants provided written
informed consent.
Data collection took place between October 2009 and July
2011. Participants completed a computer-assisted face-to-face
interview in their home, a self-complete postal questionnaire
and a centre or home-based health assessment.14
Estimation of hypertension
Blood pressure (BP) was measured by a nurse according to a
standard protocol at an ambient temperature of 20–258C.
After a period of rest, a digital automated oscillometric BP
monitor (Omron M10-IT, Omron Inc., Kyoto, Japan) with an
arm cuff (22–42 cm) was used to measure BP in one arm,
at heart height, while the respondent was seated comfortably
in an upright position. BP was recorded twice while seated
with a timed interval of 1 min between readings. The mean
systolic and diastolic readings were obtained from these two
measurements.15
Current antihypertensive medication use was recorded during
the home-based interview and classiﬁed according to the World
Health Organization (WHO) Anatomical Therapeutic Chemical
(ATC) classiﬁcation system. Combination therapy included any
combination of two or more antihypertensive medications.
Hypertension prevalence was deﬁned as systolic BP
(SBP)  140 mmHg or diastolic BP (DBP)  90 mmHg
and/or currently taking antihypertensive medications.
Respondents were asked if a doctor ever told them they had
‘high blood pressure or hypertension’, awareness of hyperten-
sion was deﬁned as endorsement of this item. Control of BP
was deﬁned as SBP, 140 mmHg and DBP, 90 mmHg
while on antihypertensive medication.
Covariates
Demographic covariates included age, sex, highest educational
attainment (primary, secondary and tertiary) and geographical
location (Dublin city or county, another town/city or a rural
area). Behavioural factors included current smoking status,
problematic alcohol consumption, body mass index (BMI)
and physical activity. Problematic alcohol consumption was
assessed as a score of 2 or more on the CAGE (Cut, Annoyed,
Guilty, Eye-opener) questionnaire.16 Height and weight were
measured by the study nurse. BMI (weight in kg/height in m2)
was classiﬁed according to the World Health Organization
(WHO) classiﬁcation—underweight: BMI, 18.5, normal
weight: BMI 18.5 and ,25, overweight: BMI 25 and
,30, obese: BMI 30. Physical activity was self-assessed
using the International Physical Activity Questionnaire (IPAQ)
short form.17 The IPAQ scoring protocol was used to categor-
ize physical activity as low (light-intensity), moderate (moderate-
intensity) or high (vigorous-intensity).18
Morbidity covariates which included the presence of dia-
betes and CVD (angina, myocardial infarction, coronary artery
bypass surgery, angioplasty/stent insertion, stroke or transient
ischaemic attack) were based on reporting ever having a
doctor’s diagnosis of these conditions or a self-report of having
undergone a procedure. Access to primary healthcare was
assessed using three mutually exclusive categories of medical
insurance status. These include, those (i) with a means tested
medical card which provides free access to general practitioner
(GP) care and heavily subsidized prescribed medicines (ii) with
private health insurance and (iii) without medical insurance.
Statistical analysis
Descriptive statistics were used to calculate prevalence and
awareness of hypertension. Crude prevalence was calculated
with survey weights applied to the estimates to adjust for se-
lection bias and additional weights to reduce non-response
bias to the health assessment component of the survey. The
population weights were calculated based on age, sex and edu-
cational attainment of the population in Ireland. Further
detail on the weights applied is available elsewhere.19
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Multivariable logistic regression was used to determine in-
dependent risk factors for awareness, treatment and control
of hypertension. Purposeful selection of variables for inclu-
sion in the regression models was based on independent vari-
ables which were signiﬁcant on bi-variate analysis and/or
deemed of importance in the literature. Adjusted odds ratios
and 95% conﬁdence intervals (CIs) are reported for the main
effects models. Underweight participants were removed from
the multivariable analysis due to small numbers. The good-
ness of ﬁt of the models was assessed using the area under
the receiver operating characteristic (ROC) curve. Statistical
signiﬁcance was set at P, 0.05. The statistical software
Stata/MP 12.1 was used to conduct the analyses.
Results
In total, 8175 respondents completed the home-based inter-
view, representing a household response rate of 62%. Of these,
5895 (72.1%) completed a health assessment. This analysis is
based on 5857 (99.3%) participants for whom BP data were
available. Table 1 outlines the characteristics of the sample.
Participants ranged in age from 50 to 98 years (mean age 63.1
SD 9.3); 51.7% were female.
The mean SBP was 136.6 (95% CI 136.0–137.2 mmHg)
for those aged 50 years and older. This increased at each
5-year age group from 129.8 (95% CI 128.8–130.8 mmHg)
in those aged 50–54 to 149.9 (95% CI 145.5–154.4 mmHg)
in those aged 85þ. The mean DBP was 82.5 (95% CI 82.1–
82.8 mmHg) for those aged 50 years and older. DBP
decreased overall from 83.5 (95% CI 82.9–84.2 mmHg) in
the youngest age group to 80.1 (95% CI 77.9–82.4 mmHg)
in the oldest group. The pattern of difference in the mean
SBP and mean DBP by age and sex is demonstrated in Fig. 1.
Weighted prevalence of hypertension was 63.7% (95% CI
62.3–65.1%) in those aged 50 years and older (Table 2). This
yields an estimated hypertension burden of 797 091 in the
population aged 50 years and older in Ireland. Hypertension
prevalence was higher in men than in women (68.7 versus
59.2%, P, 0.001) and higher in the oldest age group com-
pared with the youngest (86.6 versus 52.6%, P, 0.001).
Of those classiﬁed as hypertensive, 54.5% said they had pre-
viously been diagnosed by a doctor as hypertensive and 58.9%
were on antihypertensive treatment (Table 3). BP control
(SBP, 140 mmHg and DBP, 90 mmHg) was achieved in
just over half (51.6%) of those on antihypertensive treatment
(Table 3).
Among those on antihypertensive medication, the most
commonly used medications were angiotensin-converting
enzyme inhibitors 36.8% (95% CI 34.5–39.1%), b-blockers
36.7% (95% CI 34.3–38.9%) and angiotensin receptor
blockers 30.5% (95% CI 28.2–32.7%) (Table 4). Just over
half (52.5%) of those on treatment received combination
therapy of two or more antihypertensive medications; this
proportion was higher in the oldest age group compared with
the youngest age group (62.0 versus 44.8%, P, 0.001).
Factors associatedwith awareness, treatment
and control of hypertension
Controlling for other covariates in the model (Table 5), aware-
ness of hypertension was higher at older ages [adjusted odds
ratio (Adj OR) 1.01, 95% CI 1.00–1.02] and in women
compared with men (Adj OR 1.63, 95% CI 1.39–1.90).
Overweight (Adj OR 1.62, 95% CI 1.31–2.00), obesity (Adj
Table 1 Sample characteristics (TILDAwave 1  50 years, n ¼ 5857)
Characteristic n Weighted % 95% CI
Age
50–64 3501 58.6 56.8–60.4
65–74 1556 23.3 21.9–24.5
75þ 800 18.1 16.6–19.5
Sex
Male 2688 48.3 47.2–49.4
Female 3169 51.7 50.5–52.7
Education
Primary 1528 38.0 36.2–39.8
Secondary 2399 43.3 41.7–44.8
Tertiary 1928 18.7 17.5–19.8
Location
Dublin City or County 1521 24.5 20.9–28.0
Another town/city 1609 27.3 24.0–30.6
Rural area 2722 48.1 44.3–51.9
Current smoker 933 17.1 15.9–18.3
Alcohol CAGE  2 671 12.8 11.4–13.7
Body mass index
Underweight 32 0.5 0.3–0.7
Normal 1302 21.2 20.0–22.3
Overweight 2509 42.8 41.4–44.1
Obese 1996 35.4 34.1–36.7
Physical activity
Low 1752 31.8 30.2–33.4
Moderate 2040 34.0 32.5–35.6
High 2016 34.0 32.1–35.9
Diabetes 419 7.6 6.9–8.4
CVD history 643 12.1 11.0–13.1
Health insurance
Medical card 2612 50.1 48.3–51.9
No insurance 594 10.6 9.5–11.6
Private health insurance 2648 39.2 37.4–41.0
TILDA, The Irish Longitudinal Study on Ageing.
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OR 2.32, 95% CI 1.86–2.88) and co-morbidity with diabetes
(Adj OR 1.88, 95% CI 1.44–2.45) or with CVD (Adj OR
1.47, 95% CI 1.18–1.83) were strong predictors of awareness
of hypertension.
The adjusted odds of treatment for hypertension were also
higher at older ages, in women, in those who were overweight
or obese and in those with co-morbidity (Table 5). Those
with high levels of self-reported physical activity were less
likely to be on treatment compared with those that reported
low levels of physical activity (Adj OR 0.68, 95% CI 0.55–
0.83). Individuals with no medical insurance (Adj OR 0.69,
95% CI 0.51–0.93) or with private health insurance (Adj OR
0.82, 95% CI 0.67–0.99) were less likely to be on treatment
compared with those with a medical card.
The adjusted odds of BP control in the treated group were
lower for older adults (Adj OR 0.97, 95% CI 0.96–0.98) than
for those at younger ages. Those living in towns/cities outside
Dublin (Adj OR 1.35, 95% CI 1.05–1.75) and in rural areas
(Adj OR 1.45, 95% CI 1.14–1.83) were more likely to have
their BP controlled than those living in the greater Dublin city
or county area. A previous history of CVD was found to be
a strong predictor of BP control (Adj OR 1.82, 95% CI
1.45–2.30).
Discussion
Main finding of this study
We found a high prevalence (63.7%) of hypertension among
adults over 50 years in Ireland. Among those with hyperten-
sion, 54.5% were aware of their hypertensive status and
58.9% were on antihypertensive medication. Among those on
treatment, 51.6% had their BP controlled to levels below
140/90 mmHg. Respondents facing ﬁnancial barriers to
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Fig. 1 Distribution of weighted mean SBP and DBP in the adult population in Ireland aged 50 years and older by age group and sex (TILDAwave 1, n ¼ 5857).
Table 2 Weighted hypertension prevalence and burden in the adult population in Ireland aged 50 years and older by age and sex (TILDAwave 1, n ¼ 5857)
Age group Female (n ¼ 3169) Male (n ¼ 2688) All (n ¼ 5857)
% 95% CI Population burden % 95% CI Population burden % 95% CI Population burden
50–64 45.7 43.3–48.1 167 658 59.5 56.8–62.1 217 997 52.6 50.7–54.4 385 655
65–74 66.9 63.4–70.4 99 393 81.2 78.3–84.1 115 546 73.9 71.6–76.2 214 939
75 88.0 84.4–91.5 115 257 85.3 81.4–89.2 81 238 86.8 84.3–89.4 196 496
Total 59.2 57.3–61.0 382 309 68.7 66.8–70.5 414 782 63.7 62.3–65.1 797 091
Hypertension: SBP  140 mmHg or DBP  90 mmHg and/or currently taking antihypertensive medications.
TILDA, The Irish Longitudinal Study on Ageing.
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primary care and medication were less likely to be on antihy-
pertensive treatment compared with those without ﬁnancial
barriers.
What is already known on this topic
The highest reported hypertension prevalence for a nationally
representative survey of adults aged 50 years and older is 78%
in South Africa.20 Previous research on a subsample (aged 45
years and older, n ¼ 1207) of a nationally representative
sample of adults aged 18 years and older in Ireland found a
hypertension prevalence of 60%.12 Our study conducted on a
large older cohort is broadly consistent with the previous
hypertension prevalence estimate for older adults in Ireland.
Awareness of hypertension is low (54.5%) compared with
the level of awareness found in adults (35–84 years) in the
USA (86%) and England (64%).21 Older age and female sex
were determinants of awareness in older adults in Ireland,
raising concerns about the lack of awareness of this condition
in younger adults and in men. The ﬁndings that obesity20 and
comorbidity22 were determinants of awareness are consistent
with previous research.20,22 The lack of awareness raises ques-
tions about the ‘silent’ nature of hypertension and how a
disease that progresses silently can be identiﬁed at an early
stage if individuals do not come into contact with health
services. There is no national programme for CVD risk as-
sessment in Ireland similar to those in place in countries such
as Belgium, Germany, Luxemburg and Switzerland.23 The
National Cardiovascular Health Policy 2010–201924 recom-
mended evaluation of a structured programme for risk ascer-
tainment and management in the primary care setting to
Table 3 Weighted hypertension awareness and treatment in
hypertensive adults in Ireland by age and sex and control in the treated
by age and sex (TILDAwave 1, 50 years)
Aware
(n ¼ 3579)
Treated
(n ¼ 3579)
Controlled BP in
the treated
(n ¼ 2142)
% 95% CI % 95% CI % 95% CI
Sex
Male 48.8 46.3–51.2 55.2 52.7–57.7 50.2 46.7–53.5
Female 59.6 57.2–62.1 62.2 59.8–64.6 52.9 49.6–56.3
Age
50–64 50.3 47.8–52.7 49.1 46.6–51.5 54.9 51.5–58.4
65–74 57.5 54.4–60.6 66.7 63.7–69.6 49.1 45.4–52.7
75 years 64.0 60.1–67.9 80.1 76.9–83.3 44.2 39.5–48.9
Total 54.5 52.6–56.2 58.9 57.1–60.4 51.6 49.3–53.9
TILDA, The Irish Longitudinal Study on Ageing.
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inform the development of a model for the delivery of care.
The ﬁndings of this study highlight the urgency to implement
that recommendation in relation to prevention, detection and
management of hypertension.
Comorbidity was found to be a signiﬁcant predictor of
treatment in this cohort. This ﬁnding is consistent with previ-
ous research on quality of care and comorbidity25 and is likely
to reﬂect the higher level of contact between individuals with
comorbidity and the health system. The Irish Heartwatch pro-
gramme with a focus on secondary prevention of coronary
heart disease26 may have contributed to the higher odds of
both treatment and control in those with a CVD history. In
contrast, a diagnosis of diabetes was associated with treatment
but not control of hypertension. This appears to suggest less
emphasis on achieving BP control in diabetics compared with
those with a previous CVD history.
Individuals without medical insurance or with private insur-
ance were less likely to be treated for their hypertension
compared with those with medical cards who receive free GP
consultations and heavily subsidized medications from the
Irish Government. This is consistent with previous ﬁndings
from Ireland and elsewhere that those with free healthcare are
more likely to take cardiovascular medication27 and that
ﬁnancial burdens deter patients from getting care for their
hypertension.28 In the USA, Hispanics are less likely to have
access to health insurance29 and historically have lower BP
Table 5 Multivariable logistic regression models for Awareness, Treatment and Control of hypertension in adults aged 50 years and older in Ireland
(TILDAwave 1)
Covariate Awareness Treatment Control in the treated
Adj OR (95% CI) Adj OR (95% CI) Adj OR (95% CI)
Socio-demographic characteristics Age 1.01 (1.00–1.02)** 1.04 (1.03–1.05)*** 0.97 (0.96–0.98)***
Female 1.63 (1.39–1.90)*** 1.38 (1.17–1.63)*** 1.18 (0.97–1.44)
Education
Primary (ref) 1.0 1.0 1.0
Secondary 0.82 (0.68–0.99)* 0.85 (0.69–1.05) 1.08 (0.86–1.36)
Tertiary 1.03 (0.84–1.27) 0.96 (0.76–1.20) 1.19 (0.92–1.54)
Location
Dublin City or County (Ref) 1.0 1.0 1.0
Another town/city 0.91 (0.74–1.11) 1.23 (0.99–1.53) 1.35 (1.05–1.75)*
Rural area 0.92 (0.77–1.10) 1.18 (0.97–1.45) 1.45 (1.14–1.83)**
Behavioural characteristics BMI
Normal (ref) 1.0 1.0 1.0
Overweight 1.62 (1.31–2.00)*** 1.42 (1.13–1.78)** 0.98 (0.73–1.31)
Obese 2.32 (1.86–2.88)*** 2.02 (1.60–2.55)*** 0.96 (0.71–1.28)
Physical activity
Low physical activity (Ref) 1.0 1.0 1.0
Moderate physical activity 0.93 (0.77–1.12) 0.81 (0.66–0.99)* 0.83 (0.66–1.04)
High physical activity 0.78 (0.64–0.94)* 0.68 (0.55–0.83)*** 0.92 (0.72–1.17)
Current smoker 0.81 (0.66–1.01) 0.79 (0.62–1.00) 1.30 (0.97–1.75)
Alcohol CAGE 2 1.20 (0.96–1.50) 0.90 (0.71–1.15) 1.04 (0.77–1.41)
Comorbidity Diabetes 1.88 (1.44–2.45)*** 4.37 (3.04–6.26)*** 0.95 (0.73–1.25)
CVD history 1.47 (1.18–1.83)*** 8.52 (5.94–12.22)*** 1.82 (1.45–2.30)***
Health service access Health insurance
Medical card (ref) 1.0 1.0 1.0
No medical insurance 0.88 (0.66–1.17) 0.69 (0.51–0.93)** 0.83 (0.55–1.24)
Private health insurance 0.89 (0.74–1.07) 0.82 (0.67–0.99)* 0.90 (0.71–1.14)
Combination therapy 1.07 (0.88–1.29)
Number analysed 3116 3116 1868
Area under the ROC curve 0.63 0.74 0.60
***P, 0.001, **P, 0.01, *P, 0.05.
ROC, receiver operating characteristic; TILDA, The Irish Longitudinal Study on Ageing.
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control than non-Hispanics.30 However, the antihypertensive
and lipid-lowering treatment to prevent Heart Attack Trial
demonstrated that Hispanic-whites had 20% higher odds of
achieving BP control than non-Hispanic whites when provided
with equal access to treatment at no cost in the clinical trial
setting.31 These results contrast with an examination of racial/
ethnic disparities from 2003 to 2010 in the National Health
and Nutrition Examination Survey (NHANES) which revealed
that among those with hypertension, Mexican-Americans had
the lowest levels of treatment and control compared with
whites and blacks.32 Health-care coverage in NHANES for
those with uncontrolled hypertension was also lowest for
Mexican-Americans (59.3%) compared with blacks (77.7%)
and whites (89.4%). In Chile, a 1-year follow-up of the hyper-
tensive population in a government-ﬁnanced cardiovascular
health programme revealed that 91.5% were on antihyperten-
sive drug therapy and BP was controlled in 59.7% of patients,
providing further evidence that removing ﬁnancial barriers is
an effective strategy for managing hypertension at the popula-
tion level.33 Our ﬁndings suggest that policy directed towards
reducing the ﬁnancial barrier to healthcare and medication will
likely have a positive impact on the management of hyperten-
sion in Ireland.
Despite the availability of evidence-based clinical guidelines
for the management of hypertension34 and the acknowledge-
ment that many hypertensive patients require multiple antihy-
pertensive medications to control BP,35 just over half of
respondents in this study were treated with a combination of
two or more antihypertensive medications. Non-adherence to
medication regimes at an individual level or the absence of a
structured programme of remuneration for control of BP at a
population level may explain the low levels of treatment and
control found in this study. Pay for performance remuner-
ation for the management of chronic diseases, including
hypertension is used in some countries, e.g. the Quality and
Outcomes Framework in the UK.36 Although no discernible
effect of this system on hypertension-related clinical out-
comes was identiﬁed in the UK, possibly due to performance
targets being set too close to existing clinical practice,37 it is
reasonable to suggest that this is unlikely to be the case in
Ireland where there is no routine clinical audit of hypertension
management at a national level.
There is ongoing debate about how intensively hyperten-
sion should be treated in older adults, especially the oldest old
and whether a target reduction in SBP (e.g. 10–20 mmHg)38
or a target of ,150/80 mmHg may be more beneﬁcial39
than the target level of SBP and DBP used in this study.
While older adults were more likely to be on treatment for
hypertension than younger adults, the ﬁnding that hyperten-
sion control is lower in the older age group suggests that
either control may be more difﬁcult to achieve or that hyper-
tension is not as aggressively treated in this age group. Better
hypertension control in rural areas is an interesting ﬁnding
which conﬂicts with consistent international evidence of
poorer control in rural areas.40 This ﬁnding may reﬂect health
system differences, including the cost of primary care access in
different areas in Ireland41 and rural practices reporting fewer
private patients;42 this ﬁnding requires further investigation.
What this study adds
This study provides the most comprehensive evidence on
hypertension prevalence and burden in adults aged 50 years
and older in Ireland. Monitoring the epidemiology of hyperten-
sion is a key component in addressing the burden of hyperten-
sion. The strengths of this study include the large nationally
representative sample of community living adults, structured
collection of data on a large number of covariates and the use
of standardized protocols for measurements taken during the
health assessment.
Limitations of the study
Hypertension prevalence may be underestimated in our study as
respondents are community living, thus excluding those in long-
term residential care in whom hypertension is likely to be higher
based on the age proﬁle of residents.43 Misclassiﬁcation may
have occurred in normotensive individuals whose BP tested
high during the study, often termed ‘white coat hyperten-
sion’.44,45 This effect would overestimate the true prevalence as
white coat hypertension is estimated to occur in 15–30% of
those with elevated ofﬁce BP readings.46 Equally, some partici-
pants with true hypertension may have been misclassiﬁed as
normotensive, often termed ‘masked hypertension’.47 Masked
hypertension is estimated to occur in 8–23% of those with
normal BP readings,48 resulting in an underestimate of the
prevalence of hypertension in this study. White coat hyperten-
sion and masked hypertension create difﬁculties in classifying
hypertension based on single BP readings, as a result a minimum
of two readings are required for epidemiological studies15 and
current clinical guidelines recommend ambulatory BP meas-
urement to conﬁrm a diagnosis of hypertension.34
Conclusion
This study provides the most comprehensive estimate to date
of hypertension prevalence, awareness, treatment and control
in older adults in Ireland. The high prevalence of hyperten-
sion presents a major public health challenge which requires a
multi-sectoral response aimed at achieving healthier lifestyles
in the entire population, including weight management,
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regular physical activity, restriction of salt and alcohol and
smoking cessation. In addition to the population-wide focus,
hypertension prevention in Ireland requires an ongoing
commitment to early detection and evidence-based clinical
management of those with a diagnosis of hypertension.
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